OctoPlus wins drug delivery contract expansion
Client will proceed with PolyActive technology evaluation
OctoPlus, a Dutch drug delivery company, has won an expansion of a drug delivery technology evaluation contract with an unnamed global pharmaceutical company.
The pharmaceutical firm has decided to proceed with the evaluation of OctoPlus' PolyActive technology for an additional product candidate in its pipeline.
Under the contract, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the client's product candidate with OctoPlus' proprietary drug delivery technology.
OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.
In addition, OctoPlus is a European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.
